Larimar Therapeutics (LRMR) Enterprise Value (2013 - 2026)
Larimar Therapeutics' (LRMR) quarterly Enterprise Value came in at -$136.9 million in Q4 2025, up 25.4% YoY from -$109.1 million in Q4 2024, and up 21.99% on a QoQ basis from -$175.4 million in Q3 2025.
Larimar Therapeutics (LRMR) Enterprise Value (2013 - 2026) Analysis & Trends
Larimar Therapeutics (LRMR) has 13 years of Enterprise Value data on file, last reported at -$136.9 million in Q4 2025.
- Quarterly Enterprise Value rose 25.4% year-over-year to -$136.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$136.9 million (up 25.4% YoY) and the FY2025 annual result came in at -$136.9 million, up 25.4% from the prior year.
- Enterprise Value grew to -$136.9 million in Q4 2025, from -$175.4 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$54.9 million in Q2 2022 to a low of -$227.3 million in Q1 2024.
- A 5-year average of -$125.7 million and a median of -$115.0 million in 2022 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value sank 116.95% — and 2025, when it soared 38.72%.
- Tracing LRMR's Enterprise Value over 5 years: stood at -$70.1 million in 2021, then sank by 68.95% to -$118.4 million in 2022, then advanced by 26.71% to -$86.8 million in 2023, then sank by 111.38% to -$183.5 million in 2024, then rose by 25.4% to -$136.9 million in 2025.
- The last three Enterprise Value figures came in at -$136.9 million (Q4 2025), -$175.4 million (Q3 2025), and -$138.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Larimar Therapeutics | 452.93 Mn | 296.66 Mn | - | -156.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -156.27 Mn |
| Dec 31, 2025 | -136.85 Mn |
| Sep 30, 2025 | -175.44 Mn |
| Jun 30, 2025 | -138.52 Mn |
| Mar 31, 2025 | -157.53 Mn |
| Dec 31, 2024 | -183.45 Mn |
| Sep 30, 2024 | -203.71 Mn |
| Jun 30, 2024 | -226.06 Mn |
| Mar 31, 2024 | -227.30 Mn |
| Dec 31, 2023 | -86.79 Mn |
| Sep 30, 2023 | -95.59 Mn |
| Jun 30, 2023 | -104.20 Mn |
| Mar 31, 2023 | -111.50 Mn |
| Dec 31, 2022 | -118.43 Mn |
| Sep 30, 2022 | -124.70 Mn |
| Jun 30, 2022 | -54.92 Mn |
| Mar 31, 2022 | -62.60 Mn |
| Dec 31, 2021 | -70.10 Mn |
| Sep 30, 2021 | -84.50 Mn |
| Jun 30, 2021 | -70.60 Mn |